Pre‑existing antibodies may predict COVID‑19 vaccine effectiveness
Researchers from a national cancer institute program have discovered that antibodies already present against common microbes such as Staphylococcus aureus, RSV, and H3N2 influenza can serve as predictors of a better response to COVID‑19 vaccines. Analyzing more than 185 antigens across thousands of blood draws, the team used artificial intelligence to map patterns that separate high‑responders from low‑responders. These findings open the possibility of tailoring vaccine type, dosage, or booster schedule for individuals whose baseline immunity appears insufficient.